News

The deal will give BMS exclusive access to uniQure’s gene therapy technology platform for the development of new treatments. The companies will collaborate on up to ten targets,

Demcizumab is a humanized monoclonal antibody that inhibits Delta-Like Ligand 4 (DLL4) in the Notch signaling pathway. Under the deal, OncoMed’s demcizumab will be tested in combination with

BIND is focused on developing targeted and programmable therapeutics called Accurins. The deal was originally established in April 2013 and the timeline for Pfizer to exercise its option

Under the deal, Schrödinger could receive up to $120m, which includes preclinical milestones. Computer aided design (CAD) plays a major role in nearly all industries ranging from airplane

Nucynta is indicated to manage moderate-to-severe acute pain in adults, Nucynta ER extended release tablets are indicated to manage pain, including neuropathic pain associated with diabetic peripheral neuropathy

The new vaccines R&D center in Maryland will be the company’s third, in addition to those in Rixensart, Belgium and Siena, Italy. It will expand the company’s efforts

The deal, which includes up to $26m option premium and R&D funding, grants Astellas an option to firstly negotiate an exclusive, worldwide license at the end of Phase

The ANDA product is a generic version of Gilead Sciences’ Letairis, which is designed to treat patients with pulmonary arterial hypertension (PAH). On 01 April 2015, Gilead and

Initially, the Japanese firm will develop NBI-98854 in Japan for the chorea associated with Huntington’s disease (HD) and tardive dyskinesia. Complete commercial rights to NBI-98854 in North America,